Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis
- 4 Downloads
Discontinuation of biologic therapy in rheumatoid arthritis is attributable to various reasons, with the most important cause being insufficient response. In this study, we investigated the association between rheumatoid factor (RF) and anti-citrullinated protein autoantibody (ACPA) status and the discontinuation of tumor necrosis factor inhibitors (TNFi) therapy due to insufficient response in bio-naïve rheumatoid arthritis (RA) patients.
This study included patients enrolled in the Tsurumai Biologic Communication Registry in Japan. The crude comparison of TNFi discontinuation due to ineffectiveness between seropositive and seronegative patients was analyzed using the cumulative incidence function of competing events and Gray test. We assessed the associations between baseline patient characteristics and discontinuation of TNFi therapy due to insufficient response using Fine-Gray proportional hazard regression. Fine-Gray proportional hazard analysis considered competing events of interest, including insufficient response, adverse event, palliation, and personal reasons.
Of 1237 patients evaluated, 79.3% were positive for RF and 85.4% for ACPA; 72.6% were double positive and 11.1% were double negative. TNFi therapy had been discontinued because of insufficient response at 200 weeks in 19.8% RF-positive, 16.7% RF-negative, 23.0% ACPA-positive, and 13.8% ACPA-negative patients. There was a significantly higher discontinuation rate due to insufficient response in ACPA-positive patients than in ACPA-negative patients using Gray test, with a similar trend as that for RF status. RF positivity was significantly predictive of the discontinuation of TNFi therapy due to ineffectiveness using Fine-Gray proportional hazard regression analysis after adjusting for baseline characteristics, including age, sex, stage, class, disease activity at baseline, methotrexate use, and prednisolone use [hazard ratio 1.73 (95% confidence interval 1.07–2.80)].
• RF positivity is related to a higher discontinuation rate of TNFi therapy due to ineffectiveness.
• ACPA is not predictive of a discontinuation of TNFi therapy due to ineffectiveness.
KeywordsBiological therapy Rheumatoid factor Tumor necrosis factor Survival analysis
The authors would like to thank Crimson Interactive Pvt. Ltd. for English proofreading.
Compliance with ethical standards
Conflict of interest
N.T. has received speaking fees from Abbott Japan Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Bristol-Myers Squibb, Abbott Japan, Chugai Pharmaceutical Co. Ltd., and Pfizer Co. Ltd. N.I. has received lecture fees including service on speaker bureaus from Daiichi Sankyo Company Ltd., Takeda Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Kaken Pharmaceutical Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical KK, Bristol-Myers Squibb, Abbott Japan, Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharmaceutical, UCB Japan, and Astellas Pharma Inc. T.K. has received lecture fees from Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Bristol-Myers Squibb, Abbott Japan, Chugai Pharmaceutical Co. Ltd., and Eisai Pharma Corporation. All other authors have declared no conflicts of interest.
- 4.Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhao H et al (2016) Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-european registry analysis. Arthritis Rheumatol 68:1346–1352CrossRefGoogle Scholar
- 5.Jansen D, Emery P, Smolen JS, Westhovens R, Le Bars M, Connolly SE et al (2018) Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the agree study. RMD Open 4:e000564CrossRefGoogle Scholar
- 6.Neubauer AS, Minartz C, Herrmann KH, Baerwald CGO (2018) Cost-effectiveness of early treatment of acpa-positive rheumatoid arthritis patients with abatacept. Clin Exp Rheumatol 36:448–454Google Scholar
- 9.Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M et al (2016) Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol 68:1810–1817CrossRefGoogle Scholar
- 15.Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Oguchi T, Takagi H, Yabe Y, Kato T, Ito T, Terabe K, Fukaya N, Kanayama Y, Shioura T, Funahashi K, Hayashi M, Kato D, Matsubara H, Fujibayashi T, Kojima M, Ishiguro N, for the TBC (2012) Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai biologics communication registry (tbcr) study. Mod Rheumatol 22:339–345CrossRefGoogle Scholar
- 16.Young KA, Deane KD, Derber LA, Hughes-Austin JM, Wagner CA, Sokolove J, Weisman MH, Buckner JH, Mikuls TR, O'Dell JR, Keating RM, Gregersen PK, Robinson WH, Holers VM, Norris JM (2013) Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis. Arthritis Rheum 65:1995–2004CrossRefGoogle Scholar
- 17.van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH (2011) Classification of rheumatoid arthritis: comparison of the 1987 american college of rheumatology criteria and the 2010 american college of rheumatology/european league against rheumatism criteria. Arthritis Rheum 63:37–42CrossRefGoogle Scholar
- 25.Acaroglu E, Guler UO, Olgun ZD, Yavuz Y, Pellise F, Domingo-Sabat M, Yakici S, Alanay A, Perez-Grueso FS, Yavuz Y, European Spine Study Group (2015) Multiple regression analysis of factors affecting health-related quality of life in adult spinal deformity. Spine Deform 3:360–366CrossRefGoogle Scholar
- 26.Luo MC, Gu YQ, Puiu D, Wang H, Twardziok SO, Deal KR, Huo N, Zhu T, Wang L, Wang Y, McGuire PE, Liu S, Long H, Ramasamy RK, Rodriguez JC, van SL, Yuan L, Wang Z, Xia Z, Xiao L, Anderson OD, Ouyang S, Liang Y, Zimin AV, Pertea G, Qi P, Bennetzen JL, Dai X, Dawson MW, Müller HG, Kugler K, Rivarola-Duarte L, Spannagl M, Mayer KFX, Lu FH, Bevan MW, Leroy P, Li P, You FM, Sun Q, Liu Z, Lyons E, Wicker T, Salzberg SL, Devos KM, Dvořák J (2017) Genome sequence of the progenitor of the wheat d genome aegilops tauschii. Nature 551:498–502CrossRefGoogle Scholar
- 28.Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Cerinic MM, Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF, GISEA group (2007) Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the gisea study. J Rheumatol 34:1670–1673Google Scholar
- 29.Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A (2006) Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 33:497–500Google Scholar